Patient Conversion & Treatment Adherence
Product performance and revenue depends on whether patients are diagnosed, start treatment, and use it as intended.
Across most therapeutic areas, products lose traction at each stage:
· A large proportion of eligible patients remain undiagnosed or untreated
· Only a subset of diagnosed patients initiate therapy
· Up to 30–50% of patients discontinue treatment within the first year, depending on the condition.
These gaps translate directly into:
· lost revenue and reduced market uptake
· delayed time to treatment
· weaker real-world outcomes and evidence generation
I design and evaluate solutions that address these breakdowns, improving conversion to diagnosis, accelerating treatment initiation, and increasing long-term adherence.
Use Case 1: Personalized Engagement to Accelerate Diagnosis and Treatment
I designed a data-driven, personalized risk communication tool to help more at‑risk people recognize symptoms and seek clinical conversations earlier, increasing appropriate screening and diagnosis for under-recognized conditions.
The tool was sponsored by a Commercial team, and it has been successfully implemented in community health liaison practice, public-facing education channels, and within specialty pharmacy workflows.
For a company already holding significant market share in this therapy area, the tool functioned as a top-of-funnel accelerator—growing the pool of correctly diagnosed, treatment-eligible patients while supporting earlier intervention and better outcomes.
Use Case 2: Wearable Digital Companion to Support Treatment Efficacy
I developed the scientific foundation and measurement plan for a behaviorally informed digital companion to help people stay on treatment. This includes reinforcing the care plan between visits, flags concerning patterns earlier, and clarifies when to self-manage versus escalate to the care team.
The companion was sponsored by a Medical Affairs team, and it is expected to accompany a Phase 2b/3 randomized, double-blind and global trial.
For a company already invested in this therapy area, the companion acts as a persistence and experience engine. It is expected to reduce real‑world drop‑off, strengthening adherence and safety monitoring, and generating patient insights that support both individual care and brand performance.